ArticleJHLT open2026
Histidine-rich glycoprotein ameliorated lung ischemia-reperfusion injury in a mouse model.
Article in JHLT open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lung transplantation in 2025: a narrative review of progress, challenges, and the road ahead.Journal of thoracic disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Histidine-rich glycoprotein (HRG) is a multifunctional plasma glycoprotein involved in the regulation of various biological processes. Decreased plasma levels of HRG at 72 h after lung transplantation have been shown to be associated with severe primary graft dysfunction and poor transplant outcomes. In this study, we examined the effect of HRG supplementation on lung ischemia-reperfusion injury (IRI) in mice. Methods: The experimental mice were divided into a Sham group and three IRI groups (n=5 each) that received phosphate-buffered saline, human serum albumin, or HRG (HRG/IRI group), respectively. The lung function, lung injury, neutrophil infiltration, cellular apoptosis, inflammatory mediators, neutrophil extracellular traps (NETs), translocation status of high-mobility group box 1 (HMGB1), and hemolytic products in the injured tissue/plasma were compared among the groups. Results: The HRG/IRI group showed significantly improved oxygenation capacity and a reduced severity of lung injury as compared with the other IRI groups. The HRG/IRI group also showed significantly less severe tissue inflammation in the reperfused lung, including a lower level of neutrophil infiltration, apoptotic cells, and neutrophil-associated inflammatory mediators than the other IRI groups. Moreover, formation of NETs and HMGB1 translocation were significantly suppressed in the HRG/IRI group as compared with the other IRI groups. A significantly greater degree of scavenging of hemolytic products was observed in the HRG/IRI group than the other IRI groups. Conclusion: HRG supplementation ameliorated lung IRI in mice by suppressing inflammatory responses triggered by neutrophil-associated factors, including formation of NETs, HMGB1 translocation, and accumulation of hemolytic products.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.